September 06, 2025

Get In Touch

Cardiac Troponin I And NT-ProBNP Predict CV Risk Independent Of FRS In Psoriatic Disease

Canada: Cardiac troponin I (cTnI), independent of traditional cardiovascular (CV) risk factors may reflect atherosclerosis risk in patients with the psoriatic disease (PsD), says a recent study published in the journal Arthritis and Rheumatology.
Lihi Eder, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada, and colleagues aimed to determine whether cardiac troponin I and N-terminal pro-brain-type natriuretic peptide (NT-proBNP) in patients with the psoriatic disease is associated with carotid plaque burden and CV events development independent of the Framingham Risk Score (FRS).

For this purpose, the researchers measured carotid total plaque area (TPA) was measured in 358 participants at baseline among 1,000 patients with PsD. Automated clinical assays were used to measure cTnI and NT-proBNP. The association between carotid atherosclerosis and cardiac biomarkers was assessed by multivariable regression after adjusting for CV risk factors. Using measures of risk discrimination and reclassification, improvement in the prediction of CV events beyond the FRS.
Salient findings of the study include:
In univariate analyses, cTnI (β coefficient 0.52) and NT-proBNP (β coefficient 0.24) were associated with TPA.
After adjusting for CV risk factors, the association remained statistically significant for cTnI (adjusted β coefficient 0.21), but not NT-proBNP.
Among 1,000 patients with PsD assessed for CV risk prediction, 64 patients had incident CV events.
When comparing a base model (with the FRS alone) to expanded models (with the FRS plus cardiac biomarkers), there was no improvement in predictive performance.
To conclude, "cTnI may indicate a risk for atherosclerosis in patients with psoriatic disease independently from traditional cardiovascular risk factors."
"cTnI and NT-proBNP are associated with incident CV events independent of the FRS, however, further study of their role in CV risk stratification is warranted," they wrote.
Reference:
Colaco K, Lee KA, Akhtari S, Winer R, Welsh P, Sattar N, McInnes IB, Chandran V, Harvey P, Cook RJ, Gladman DD, Piguet V, Eder L. Association of Cardiac Biomarkers with Cardiovascular Outcomes in Patients with Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. Arthritis Rheumatol. 2022 Mar 8. doi: 10.1002/art.42079. Epub ahead of print. PMID: 35261189.

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!